Radioiodine therapy is applied for the treatment of differentiated thyroid cancer (DTC), including papillary thyroid cancer (PTC), due to the improved uptake of DTC cells based on the expression of the sodium iodide symporter (NIS). This evidence concerns the gene SLC5A5 and thyroid gland papillary carcinoma.